Travere Q3 2026: FILSPARI Sales Hit $200M, Net Loss Widens

Travere Therapeutics reported third-quarter 2026 U.S. net product sales of $220.2 million on 2 November 2026, up from $113.2 million a year earlier, with FILSPARI (sparsentan) contributing $200.2 million, a 120% year-over-year increase. The company posted a net loss of $52.3 million, or $0.55 per basic share, swinging from net income of $25.7 million a year earlier, after recognizing a $113.1 million IPR&D charge tied to its civorebrutinib licensing deal with Everest Medicines.

Context — why Travere's Q3 2026 results matter now

The quarter captures a company in commercial expansion and pipeline reinvestment at the same time. FILSPARI's $200.2 million quarterly total compares with $113.2 million for all U.S. net product sales a year earlier, meaning the single product now exceeds the entire prior-year product base.

That trajectory matters because Travere has been spending to widen FILSPARI's label reach. SG&A rose to $98.4 million from $71.0 million, which the company attributed to commercial investment behind the recent FSGS launch and ongoing IgAN commercialization.

R&D climbed to $70.3 million from $51.9 million, driven by the Phase 3 HARMONY Study of pegtibatinase and manufacturing for classical homocystinuria. The company is funding both fronts from product revenue rather than a single late-stage asset.

The $113.1 million IPR&D expense is the mechanical reason GAAP net income flipped to a loss. It reflects the closing of the exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an investigational oral BTK inhibitor.

Macro conditions are not a stated factor in the report. The company did not tie its results to interest rates, inflation or broader market conditions, so the swing is best read as product growth offset by deliberate pipeline and commercial spending.

The leadership change adds a timing wrinkle. Bradley L. Campbell succeeds Eric Dube as president and CEO effective 1 December 2026, meaning the incoming chief executive inherits a commercial franchise already at scale and a pipeline entering late-stage planning.

Data — what the numbers show

FILSPARI U.S. net product sales reached $200.2 million in the third quarter of 2026, up 120% year over year. For the nine months ended 30 September 2026, FILSPARI sales were $446.4 million, up 104% year over year.

Total U.S. net product sales were $220.2 million for the quarter versus $113.2 million a year earlier, and $506.0 million for the nine-month period versus $283.9 million.

Metric	Q3 2026	Q3 2025
FILSPARI U.S. net sales	$200.2M	~$91M implied
Total U.S. net product sales	$220.2M	$113.2M
R&D expense	$70.3M	$51.9M
SG&A expense	$98.4M	$71.0M
Net income (loss)	-$52.3M	+$25.7M

The company received 1,932 new patient start forms during the quarter, spanning IgAN and FSGS. Non-GAAP adjusted R&D was $63.2 million and adjusted SG&A was $81.7 million, both above prior-year levels.

Non-GAAP adjusted net loss was $29.6 million, or $0.31 per basic share, versus adjusted net income of $52.8 million a year earlier. Cash, cash equivalents and marketable securities stood at $471.8 million as of 30 September 2026.

The report gives no peer or sector comparison, so none is presented here.

Analysis — what it means for markets and healthcare tickers

The central tension is growth against spend. FILSPARI's 120% quarterly growth is running well ahead of the 104% nine-month pace, which implies the FSGS launch is adding to, not cannibalizing, the IgAN base.

That matters for the rare-disease nephrology space, where FILSPARI competes for the same nephrologist attention as other IgAN-directed therapies. Travere's own framing is that it remains early, citing more than 100,000 addressable patients across IgAN and FSGS.

The $113.1 million IPR&D charge is a one-time accounting event, not recurring cash burn, but it obscures the underlying operating picture for readers scanning headline net loss. The non-GAAP loss of $29.6 million is the cleaner read on operating performance, and it still widened from prior-year profitability.

The limitation to weigh: patient start forms measure prescriptions initiated, not revenue recognized or patients retained. The report does not disclose discontinuation rates or gross-to-net pricing, so the durability of the $200.2 million run rate cannot be verified from these figures.

On positioning, the report offers no share-count, float or ownership data. What it does show is a company with $471.8 million in liquid resources funding two late-stage programs, which reduces near-term financing pressure relative to a pre-revenue biotech.

For sector exposure, Travere sits in the small-cap nephrology cohort, where pipeline readouts rather than quarterly revenue often drive share price. The civorebrutinib IND and HARMONY topline are the events that re-rate that cohort.

Outlook — what to watch next

The company said it plans to submit a U.S. IND for civorebrutinib by year-end 2026 to enable dosing studies, with subsequent regulatory engagement to support late-stage studies. That is the nearest hard catalyst.

Pegtibatinase topline results from the Phase 3 HARMONY Study are guided to the second half of 2027. The trial is expected to enroll approximately 70 patients aged 12 to 65 with plasma total homocysteine levels of at least 50 µM.

The SPARLIGHT Phase 4 study in high-risk FSGS is targeting first patient in by the end of 2026. SPARX data in post-transplant recurrent IgAN or FSGS is anticipated in 2027.

The CEO transition takes effect 1 December 2026, with Dube staying as executive advisor through 15 February 2027. The report names no price levels, moving averages or yield thresholds, so none are cited here.

Frequently Asked Questions

What does Travere's Q3 2026 net loss mean for retail investors?

The $52.3 million GAAP net loss was driven largely by a $113.1 million IPR&D charge from the Everest Medicines civorebrutinib licensing deal, not by operating deterioration. On a non-GAAP basis, the adjusted net loss was $29.6 million. Revenue grew 95% to $220.2 million, so the loss reflects reinvestment and a one-time charge rather than collapsing demand.

What happens next for Travere Therapeutics?

The company said it plans a U.S. IND submission for civorebrutinib by year-end 2026, with pegtibatinase Phase 3 HARMONY topline guided to the second half of 2027. SPARLIGHT first patient in is targeted by end of 2026. Bradley Campbell becomes CEO on 1 December 2026, succeeding Eric Dube.

Why did FILSPARI sales grow 120% year over year?

Travere attributed the growth to patient demand across IgAN and FSGS, with 1,932 new patient start forms received in the quarter. The company said FILSPARI continues to hold a foundational role in IgAN while showing early launch momentum in FSGS. The report does not break out revenue by indication or disclose pricing.

Bottom Line

FILSPARI's 120% growth is real, but a one-time $113.1 million licensing charge, not operations, turned the quarter to a loss.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.